Helsinki: Anyone who has fallen ill while travelling within Europe knows the absurdity. A patient summary held by a doctor in one member state is, for practical purposes, invisible to a hospital a few hundred kilometres away, and a prescription written at home may be impossible to dispense abroad. The European Health Data Space, a regulation that began to apply this spring, is the bloc’s attempt to dismantle those walls, and it is one of the most ambitious data projects the Union has ever attempted.
The framework rests on two pillars that pull in different directions. The first, primary use, concerns the patient in front of the doctor. It is meant to give people genuine access to their own electronic records and to let that information follow them across borders, so that a clinician in one country can read a patient summary or honour an electronic prescription issued in another. The second, secondary use, is more contentious. It allows health data, stripped of direct identifiers, to be made available to researchers, public health bodies and innovators under controlled conditions, on the argument that Europe’s vast clinical records are a resource that could speed discoveries if responsibly shared.
The regulation took effect in stages rather than at a single stroke. Its provisions began applying from late March, but the heavy machinery arrives later. Member states have been required to designate national digital health authorities to oversee the rollout, and vendors of electronic health record systems face certification requirements intended to force interoperability between products that today rarely speak to one another. The most consequential deadlines stretch into the latter part of the decade, when the Commission must adopt detailed implementing rules and when the cross-border exchange of priority data categories, patient summaries and prescriptions chief among them, is due to become a working reality.
That long runway is both a strength and a vulnerability. It gives health systems, many of them stretched and under-digitised, time to prepare. It also means the project’s promises will not be tested for years, and Europe’s record on large digital infrastructure is uneven. Building registries, certifying software and persuading dozens of national systems to adopt common standards is the kind of unglamorous work that rarely goes smoothly.
Privacy is the other shadow over the project. The secondary-use provisions have unsettled patient advocates and data-protection specialists who worry that even anonymised health information can be re-identified, and who question whether ordinary people fully understand how their records might be used for research. The regulation builds in safeguards, including the use of privacy-enhancing technologies and a system of permits governing who may access what, but the balance between unlocking medical research and protecting the most sensitive information anyone holds is a line that will be redrawn many times as the rules bed in.
The prize, if the project works, is considerable. A continent that can share clinical data securely could spot drug side effects faster, run larger studies and spare patients the maddening experience of starting from scratch every time they cross a border. Whether the data space delivers that or becomes another half-built piece of European infrastructure depends less on the regulation itself than on the patient, expensive work of implementation now beginning in health ministries across the bloc.
